Engineered immune cells take on rare leukemia

NCT ID NCT04815356

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-phase trial tests a new treatment for hairy cell leukemia (HCL) that has come back or not responded to standard care. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. Up to 27 adults will receive chemotherapy followed by an infusion of these modified cells, and researchers will monitor safety and whether the cancer shrinks or disappears.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-CD22 CAR T cells (a type of immune cell therapy)
What this could lead to: If successful, this could provide a new treatment option for people with hairy cell leukemia who have not responded to standard therapies.
What could go wrong: This is an early Phase I trial with only 27 participants, so the treatment may not work or could cause serious side effects. It is too soon to know if it will be effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hairy cell leukemia hairy cell leukemia variant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAIRY CELL LEUKEMIA HAIRY CELL LEUKEMIA VARIANT

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.